Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Excess visceral adiposity is strongly associated with increased risk of cardiovascular events and all-cause mortality, even after accounting for body mass index (BMI)
While much has been published on cellular expression of GPCRs, including the GLP-1R, when evaluating the validity of such data it is key to consider the methodologies applied [e.g., immunohistochemistry (IHC), in situ hybridization (ISH), polymerase chain reaction (PCR), in situ ligand binding (ISBL)]
Mizushima, N., Levine, B., Cuervo, A
In February 2025, Gan & Lee Pharmaceuticals (hereafter referred to as "Gan & Lee," stock code: 603087.SH) unveiled that the first participant was successfully dosed in a large-scale Phase 3 clinical trial (OPTIMUM-2) of Bofanglutide, a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) independently, in Chinese participant with type 2 diabetes mellitus (T2DM)
US$ 22.86
US$ 23.56
US$ 24.92
